Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3359609 plus pembrolizumab and 5-fluorouracil-platinum chemotherapy versus placebo plus pembrolizumab and 5-fluorouracil-platinum chemotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma
2019-003981-42Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing GSK3359609 combination arm with Placebo control arm (2 arms). Primary endpoints: Overall survival in total population, Overall survival in PD-L1 CPS 1 or greater population and 1 more. Started Sep 2020; status: completed.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-003981-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003981-42.